Thank you going ago. few and We quarter of market, you and good we announced afternoon, everyone. probably but XX, for shocked I the shell year-ended financial about our press December minutes what’s must on results the are in on. know fourth most a XXXX
that forward-looking begin I though, Before statements. comments some will include to listeners I'd today our remind like
risks the and forward-looking press materially of which results, These are our today's statements number in statements. involve differ in uncertainties, release reports outlined a the may those from and SEC. in and filings with Actual
On non-GAAP this measures. to call, financial also we’ll refer
measures XX-months on in months www.celcuity.com release. earnings the Investors find three December today's included is for ended also our table available our You non-GAAP can financial financial a release and XXXX, the press release press in section. website reconciling which XX, Today's was the measures GAAP under to
I'm our quarter I'll a pleased fourth Hahne, then particular, Vicky make our our me review of development discussions on the line details product open trials. we’ll outlook. the our and few the clinical will also projects, more a status with as and some comments general like on with follow-up CFO. collaboration on provide I'd our In items to questions. as to for well have results, call, Vicky today
that of of guide could on targeted patients based cancer XX% of oncologist actionable XX small cancer a to from patients. past their estimate years only today, a cancer use molecular selection typically Well reports a an lack that medicine. therapy the molecular benefiting made for so limitation biomarker, the proportion an are patients advancements Recent or roughly over
diagnostics of this therapies. for a Celcuity XX% is patients need found are today eligible We unmet address unmet with cancer need. targeted who not for new at It thus huge to
which signaling, dysregulated driving cellular CELx is previously activity platform we oncogenic which diagnosed many called CELsignia, cancers. the Our as underlying
directly The a patients targeted pathway mechanism signaling that therapies corresponds to a disease mechanism with we matching action. diagnose dysregulated have a of
to indications therapies Our help patients to identified. is strategy companies the obtain at for CELsignia treat targeted pharmaceutical tests the new
characterize the hard for of Since this molecular applications our to strategy. to the CELsignia signaling capability too can create CELsignia a business leverage is platform complex expand tests team To R&D strategy, platform. our you working is to regulated for our proprietary our execute
may the New who pharmaceutical positively collaborations tests of number increase number expand the of we potential patients and pursue. impact can
significant in made advancing of the I’m XXXX. tests quarter excited we report additional CELsignia to fourth progress that
December, Breast CELsignia As we Symposium. pre-clinical studies we the reported in where presented Cancer San at Test Antonio new results from PIXK our
The PIKX-mutational how benefit identify signaling using to studies PIXK-involve to and we PIXK provide from specific demonstrate sensitive status measure CELsignia more likely platform a method may our than most patients inhibitors. presented to
Our of platform our analyzing insights PIXK by cells. provides test an signaling CELsignia unique on can excellent tumor activity case living study obtain
for PIXK cancer breast with inhibitor. are certain in with treatment eligible mutations are Today, patients a PIXK only
cancer breast identify less to important recent maybe of suggested recently than PIXK This PIXK PIXK activity alpelisib, approved However, mutational involve measure measurement than PIXK that status PIXK inhibitor. results eligible more stage us late responded patients trial XX% of of clinical to inhibitors. for to signaling mutated a to patients
G-protein-couple identified cancers. had We receptors PIXK breast some GPCRs length researchers a and cancer that knew between in or signaling activity
tests to apply With is using to this linkage. this we the not CELsignia molecular platform, it could possible confirm clinic. our However, discovery
that can Ultimately cancer ability develop involving signaling were and allowed developed complex test treatment with GPCR tumors with our play pathways activity new also such PIXK PIXK role to dysregulated whether to unique a methods to to identify signaling, identified patients involved. First, us second pathway nodes we promoting multiple certain identify we known our in with as PIXK inhibitors. analyze
activity cancer for molecular HERX-negative third to is cancer. has now Celcuity one signaling identify in dysregulated patients. the potential This three breast tests CELsignia breast for by undiagnosable our test up to
a are by tests once our patient tests CELsignia cannot identify. diagnosed molecular is if current three So,
companies offers new the a opportunity test number or therapies their eligible Each potential for for patients to to pharmaceutical expand targeted obtain of indications.
and the successful incredible groups, outcomes indications new to patients. breast working For have treat the cancer pharmaceutical companies an for with gain of on these will to impact drug approval we
for We efforts breast to hope Consistent for cancer with fourth strategy, in during for we of preclinical the also complete the this are our quarter. test to tests Development new studies patients. breast develop our test continuing additional cancer our advanced XXXX.
the In in for committed tests can cell tests all to addition a of range offering cancer, of number also CELsignia types. we breast perform maximizing tumor to we’re
cancer uniquely breast ovarian as research cancer valuable Our insights into has affects another given cancer. that
Association originally new first We’re yet our of for we pleased of been American to The report that cancer test has has set. postponed announce concerns. at for been This was study Research. Meeting late not scheduled April, Cancer because will CELsignia related but date results meeting the the ovarian XXXX Annual preclinical COVID-XX for for
therapeutic therapy limited a This of cancer five-year cancer options year new oncogenic targeted from a a cancer, women a have test hyperactive XX,XXX ovarian signaling significant additional than less ovarian activity. ovarian rate unmet is has whose intended die XX% tumors need undiagnosed disease a range to for identify patients There survival Nearly options. a patients. for thus of that is and subgroup
initiate CELsignia expect new pharmaceutical intended our obtain diagnostic, to tumor cancer XXXX. We pharmaceutical later clinical expand ovarian collaborating discussions for companies help for on trials companion in treatment will companies test with challenging indications be and options this about drug would a to As type.
and trial to finalize to efforts continued with several clinical pharmaceutical sponsors Our progress. collaborations companies clinical
with of a number and prominent We’re in discussions centers. and active oncologists companies
patients of to is CELsignia identified goal various in cancer targeted by Our evaluate our breast tests. the efficacy therapies
could therapies population approval our believe treat identifies. lead if would, to either FDA what enable collaborations ultimately the combination collaborations helping a success study of patient these drugs these or tests a potential us The to range These finalized single to agents. we gain
very some companies, in or required clinical four cases We but collaborations related involve will time the year, pharmaceutical is remain that confident collaborations Celcuity, between parties. three close sponsor, to agreements we the two the and this several since finalize the significant
I’d the trials. addition sponsoring sites clinical new now to activated FACT group that an turn to We the of clinical trial. like of the our clinical NSABP, has is on completed to have trial our now participating. update XX Genentech largely sites X
but expect We of soon, the sites adding completed. is get would more activity largely several activated
or however, these yet as that enrollment the new expected. sites expected rate To the increase sites impacted NSABP not new We trial. immediately enrollment rate date, we these have would for the
early much As patients patients in NSABP more cancer and the are rate. to difficult it in project with clinical previously stage makes discussed, trials to enrollment accuracy for we this hard enroll later stage
and as this be than slower early-to-mid-XXXX a trial given in nine from available result, results expect expected months these enrollment results will So, we later. from new approximately the sites, interim final now
of pan-HER chemotherapy clinical progressing. FACT Nerlynx, The trial is X and and it Puma is safety Biotechnology's the inhibitor, efficacy evaluating
are interim X-XX months this in mid-XXXX final from We results trial later. and expecting results approximately
with advisory clinical expanded the that few And our over fuel or to scientific board companies with collaborate pharmaceutical efforts past SAB trials, our months. we finally, in conjunction
past months. nationally several the recognized We’re announce over to our that medical have few pleased SAB joined oncologists
the members Assistant Translational Precision Filip Medical Oncology Janku, Dr. Center co-leader and of Center; Cancer Dr. Cancer Anderson MD at Ben Anderson of at Center. SAB Our Dr. new Director Park, Cancer Bora Breast Vanderbilt Director Medical Clinical Research MD Center; of and Lim, University the and Research include: Program Professor,
them collaborate gain with We’re as well on as future to to excited about potentially insights, their the clinical trials. opportunities
to The Board former our provides recent Dr. Pfizer translational great of company. medicine VP Buller at experience also Directors addition of Translational Medicine clinical to and our Richard of
expected we’re So made our about trial, very during the progress while quarter. the enrollment first remain excited slower we overall, disappointed the of in than we
results. So, now to to like review financial our to over turn Vicky I’d it
